Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A P Ijzerman

Showing results (31-40 of 145) with videos related to

Pageof 15
Sort By:
Journal of Medicinal Chemistry|February 21, 1992
A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptorE M van der Wenden, A P Ijzerman, W Soudijn
Trends in Pharmacological Sciences|December 22, 1999
TinyGRAP database: a bioinformatics tool to mine G-protein-coupled receptor mutant dataM W Beukers, I Kristiansen, A P IJzerman, et al.
Biochemical Pharmacology|August 15, 1990
Chemical modification of adenosine A1 receptors. Implications for the interaction with R-PIA, DPCPX and amilorideA Garritsen, A P Ijzerman, M W Beukers, et al.
British Journal of Pharmacology|April 26, 2000
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discoveryR A de Ligt, A P Kourounakis, A P IJzerman
Progress in Medicinal Chemistry|January 5, 2002
The adenosine A3 receptor and its ligandsJ E van Muijlwijk-Koezen, H Timmerman, A P Ijzerman
Journal of Medicinal Chemistry|February 1, 1986
Mapping the turkey erythrocyte beta receptor: a distance geometry approachM R Linschoten, T Bultsma, A P IJzerman, et al.
Drug Design and Discovery|January 1, 1992
Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptorA P IJzerman, P J Van Galen, K A Jacobson
Biochemical Pharmacology|February 13, 2001
Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptorA Kourounakis, C Visser, M de Groote, et al.
Biochemical Pharmacology|August 6, 2000
Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulationZ G Gao, Q Jiang, K A Jacobson, et al.
European Journal of Pharmacology|January 1, 1994
Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016M W Beukers, C J Kerkhof, A P IJzerman, et al.
Pageof 15

Showing results (31-40 of 145) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|February 21, 1992
A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptorE M van der Wenden, A P Ijzerman, W Soudijn
Trends in Pharmacological Sciences|December 22, 1999
TinyGRAP database: a bioinformatics tool to mine G-protein-coupled receptor mutant dataM W Beukers, I Kristiansen, A P IJzerman, et al.
Biochemical Pharmacology|August 15, 1990
Chemical modification of adenosine A1 receptors. Implications for the interaction with R-PIA, DPCPX and amilorideA Garritsen, A P Ijzerman, M W Beukers, et al.
British Journal of Pharmacology|April 26, 2000
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discoveryR A de Ligt, A P Kourounakis, A P IJzerman
Progress in Medicinal Chemistry|January 5, 2002
The adenosine A3 receptor and its ligandsJ E van Muijlwijk-Koezen, H Timmerman, A P Ijzerman
Journal of Medicinal Chemistry|February 1, 1986
Mapping the turkey erythrocyte beta receptor: a distance geometry approachM R Linschoten, T Bultsma, A P IJzerman, et al.
Drug Design and Discovery|January 1, 1992
Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptorA P IJzerman, P J Van Galen, K A Jacobson
Biochemical Pharmacology|February 13, 2001
Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptorA Kourounakis, C Visser, M de Groote, et al.
Biochemical Pharmacology|August 6, 2000
Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulationZ G Gao, Q Jiang, K A Jacobson, et al.
European Journal of Pharmacology|January 1, 1994
Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016M W Beukers, C J Kerkhof, A P IJzerman, et al.
Pageof 15